Sort   by:  
 Page size 
UnknownRituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Not available
S-EPMC4876343 | biostudies-literature
UnknownSelective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.
Not available
S-EPMC4186455 | biostudies-literature
ProteomicsChronic lymphocytic leukaemia cells exhibit functional heterogeneity in the unfolded protein response: a proteomic study
Genomic, epigenomic, and transcriptomic studies have provided only a partial explanation of disease heterogeneity in chronic lymphocytic leukaemia (CLL). Since mRNA and protein expression do not always correlate, CLL heterogeneity was investigated using global cellular proteomics. Sequential Window...
ORGANISM(S): Homo sapiens (Human) 
2025-08-04 | PXD058183 | Pride
Chronic lymphocytic leukaemia Disease heterogeneity Response to therapy Unfolded protein response 
UnknownFinal Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Not available
S-EPMC10448866 | biostudies-literature
ProteomicsCLL iTRAQ3 - Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia
The mutational status of the immunoglobulin heavy chain variable region (IGHV) defines two clinically distinct forms of chronic lymphocytic leukemia (CLL) known as mutated (M-CLL) and un-mutated (UM-CLL). To elucidate the molecular mechanisms underlying the adverse clinical outcome associated with U...
ORGANISM(S): Homo sapiens (Human) 
2016-06-27 | PXD001516 | Pride
Human Leukemia Itraq Mutation 
ProteomicsCLL iTRAQ2 - Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia
The mutational status of the immunoglobulin heavy chain variable region (IGHV) defines two clinically distinct forms of chronic lymphocytic leukemia (CLL) known as mutated (M-CLL) and un-mutated (UM-CLL). To elucidate the molecular mechanisms underlying the adverse clinical outcome associated with U...
ORGANISM(S): Homo sapiens (Human) 
2016-06-27 | PXD001515 | Pride
Human Leukemia Itraq Mutation 
ProteomicsCLL iTRAQ1 - Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia
The mutational status of the immunoglobulin heavy chain variable region (IGHV) defines two clinically distinct forms of chronic lymphocytic leukemia (CLL) known as mutated (M-CLL) and un-mutated (UM-CLL). To elucidate the molecular mechanisms underlying the adverse clinical outcome associated with U...
ORGANISM(S): Homo sapiens (Human) 
2016-06-27 | PXD001512 | Pride
Human Leukemia Itraq Mutation 
UnknownEvaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
Not available
S-EPMC4636148 | biostudies-literature
UnknownPlasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Not available
S-EPMC11869088 | biostudies-literature
UnknownCDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Not available
S-EPMC10983964 | biostudies-literature
Sort   by:  
 Page size